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One of the major outer membrane proteins of gram-negative bacteria is a murein lipoprotein first reported by Braun and Rehn (2) . Later, Inouye et al. also reported the existence of two different forms, free and bound forms of lipoprotein (6) . Some unique features of the biosynthesis of lipoprotein were also described (5) . Lipoprotein is first synthesized as prolipoprotein, which is then converted to lipoprotein by the prolipoprotein-processing enzyme. This enzyme hydrolyzes the so-called signal sequence in the amino terminus of prolipoprotein.
Globomycin, a peptide antibiotic (7, 8, 10 ), inhibits the above-mentioned processing enzyme, resulting in decrease of the free form of lipoprotein and accumulation of prolipoprotein (9) . In this paper we present evidence which indicates the existence of the murein-bound form of prolipoprotein, and we discuss the biosynthesis of lipoprotein.
Exponentially The envelope fraction was obtained as described above except that 100 ml of M9-glucose medium was used to grow the cells of E. coli B. The murein fraction was then isolated from this envelope fraction, either immediately or after incubation in 10 mM sodium phosphate buffer (pH 7.0) at 370C for 4 h, by hot 4% SDS treatment as described by Braun and Rehn (2) . The murein fraction thus obtained was digested with 1,000 ,ug of lysozyme per ml in the same buffer and subjected to 7.5% SDS-polyacrylamide gel electrophoresis after solubilization as described above. The electrophoretic pattern of the bound fonn of lipoprotein synthesized in the presence of 5 jug of globomycin per ml was somewhat different from that of a normal one ( Fig. 2A) in the following points.
(i) There were two (or four) peaks in the antibiotic-treated murein fraction, but only one peak in the normal one.
(ii) In the antibiotic-treated murein fraction, one ( 6 N HCI at 1100C for 20 h under reduced pressure. Amino acid analysis was performed using a Hitachi KLA-5 automatic amino acid analyzer. As shown in Table 1 , with the exception of those amino acids present in the peptidoglycan, the amino acid analysis of the bound form of lipoprotein of the untreated cells revealed a composition similar to that of lipoprotein reported by Braun and Rehn (2). In the murein fraction of the globomycin-treated cells, however, there existed additional amino acids involved only in the signal sequence of prolipoprotein (6) . From the result of the amino acid analysis, 30% of the bound form of lipoprotein in the murein fraction is assumed to be in the form of prolipoprotein. The protein(s) that migrated slower than the free form of prolipoprotein in the electrophoretic pattern shown in Fig. 2A was, therefore, suggested to be the mureinbound prolipoprotein.
As described previously (9) , the free form of prolipoprotein, accumulated in the presence of globomycin, converted to lipoprotein by incubation of the envelope fraction in the absence of the antibiotic (Fig. 1B) . In the present experiment, however, conversion of the bound form of prolipoprotein to lipoprotein was rarely observed in the same incubation procedure (Fig.  2B) .
The existence of the bound form of prolipoprotein may not imply that the bound form of lipoprotein is processed from the bound form of prolipoprotein. The bound form of lipoprotein may be processed from the free form of lipoprotein under normal conditions (5), but in the globomycin-treated cells, the enzyme which catalyzes the transpeptidation between lipoprotein and peptidoglycan also may catalyze between prolipoprotein and peptidoglycan to form the bound form of prolipoprotein (Fig. 3) 
